Interventional therapy for hepatocellular carcinoma is a kind of regional local chemotherapy by injecting anti-cancer drugs or embolic agents into the hepatic artery through the femoral artery cannula. It is currently the preferred method of non-open surgery for hepatocellular carcinoma, and its efficacy has been confirmed. Treatment methods Among hepatocellular carcinoma, vascular interventional therapy is the most clinically used. It is mainly selective hepatic artery perfusion therapy, selective hepatic artery embolization, and selective hepatic artery chemoembolization. The main physiological basis is that the blood supply of normal hepatocytes is 20%-25% from hepatic artery and 75%-85% from portal vein. In primary hepatocellular carcinoma, 90%-95% of the blood supply comes from the hepatic artery, which provides the anatomical basis for vascular intervention for hepatocellular carcinoma to treat the tumor. The specific technical methods of all three are the same, that is, a small incision of about 3-5 mm is punctured on the skin, a tube is inserted from the artery to the blood supplying artery of hepatocellular carcinoma, and then the drug is administered through the catheter, the difference lies in the different drugs administered. Selective hepatic arterial infusion (TAI) therapy involves intra-arterial infusion of the drug through a catheter at a dose equal to or less than that administered intravenously. This allows for higher local drug concentrations in the target cells and longer contact time with the lesion, and reduces the total systemic dose of drugs, resulting in improved efficacy and fewer side effects. The efficacy of chemotherapeutic drugs is positively correlated with the effective blood concentration of the drugs at the tumor site and the contact time of the drugs with the tumor. In addition, Chinese medicinal preparations and CIK cells can also be infused for successive immunotherapy.